FN Media Group Presents USA News Group News Commentary
VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ -- USA News Group - Despite the approval for the Comirnaty vaccine from Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) by the FDA back in August, vaccine hesitancy in the USA persists and is unlikely to disappear. Now with what PFE/BNTX are calling encouraging results for their Covid-19 vaccine trial on kids in hand, it's expected that parents are going to be even more hesitant to jab their own children. Reports of heart inflammation are adding fuel to the fire, spurning closer studies into myocarditis risk taking place inIsrael and the USA, and Canada particularly with mRNA vaccines such as those from Pfizer, BioNTech and Moderna, Inc. (NASDAQ:MRNA), while earlier this year multiple European countries suspended the use of AstraZeneca PLC (NASDAQ:AZN) over worries about blood clots. While these manufacturers are standing by their safety and efficacy, a new study on the hapten-modified spike protein used in the BVX-0320 SARS-CoV-2 vaccine from BioVaxys Technology Corp. (CSE:BIOV) (OTCQB:BVAXF) is giving hope to another method that could potentially mitigate some of these abnormal life-threatening side effects.
Albeit rare, life-threatening side effects, such as abnormal blood clotting or myocarditis can be the result from either recombinant full-length or partial Spike protein—which are found in currently available vaccines. These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
The BVX-0320 vaccine for Covid-19 from BioVaxys Technology Corp. (CSE:BIOV) (OTCQB:BVAXF) comprises a portion of the spike protein that is modified by utilizing haptenized protein technology based on the work of the immunologist and Nobel laureate Dr. Karl Landsteiner.
James Passin, CEO of BioVaxys, stated: "Haptenization, as a method to inhibit the ACE2-binding ability of the s-spike protein, while increasing its immunogenicity, may prove to play a critical role in global Covid-19 vaccine development and deployment strategies, as public health authorities consider options for repeated seasonal vaccine boosters in the context of reported, albeit rare, adverse effects and apparent waning immunity."
Biovaxys believes that the haptenized spike protein has much diminished ability to bind to ACE2, which would result in much diminished vaccine toxicity.
The company's belief appears to be backed by the conclusions of the scientifically groundbreaking peer-reviewed research paper, published in the Journal of Hematological Oncology. The paper concluded that the Receptor Binding Domain of the SARS-CoV-2 spike protein binds to the ACE2 receptor and that this binding of SARS-CoV-2 to ACE2 prevents the enzyme from converting angiotensin II, potentiating pulmonary and cardiovascular issues.
"Biovaxys will compare the binding of haptenized spike protein with the non-haptenized," explained Chief Medical Officer of Biovaxys, David Berd, MD. "The results could provide evidence that our vaccine has lowered potential for some of the observed serious vaccine side effects."
Accompanying its commentary on the new findings from the research paper, BioVaxys also announced it has entered into an agreement with a subsidiary of one of the largest pharmaceutical companies in the world, with a market capitalization of US$102 billion Merck KGaA.
Through the deal, the subsidiary—named Millipore—will manufacture a supply of GLP-grade BVX-0320, the Company's SARS-CoV-2 vaccine candidate for the study.
Last summer, Millipore produced similar yields of BVX-0320 last summer for the BioVaxys' animal immune response studies. This time, Millipore will be incorporating in the manufacturing the recently produced purified recombinant s-protein produced by BioVaxys' bioproduction partner, the $63-billion Chinese bio manufacturer WuXi Biologics.
BioVaxys President & Chief Operating Officer Kenneth Kovan said, "The production of the recombinant s-protein using WuXi Biologics' proprietary cell expression system is a significant milestone for Biovaxys, as we not only have a high production yield of protein, but also now have the ability and know-how to produce protein in large scale with the level of purity, consistency and protein characterization required by the FDA for our clinical studies and commercial-scale yields."
BioVaxys is currently finalizing arrangements with a major US academic research institution to collaborate on the study. The company has already previously announced research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320.
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) recently announced "positive topline results" from a pivotal trial of Covid-19 vaccine in children 5 to 11 years. The trial used a two-dose regimen of 10 µg administered 21 days apart, a smaller dose than the 30 µg dose used for people 12 and older. Antibody responses in the participants given 10 µg doses were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age immunized with 30 µg doses.
"These trial results provide a strong foundation for seeking authorization of our vaccine for children 5 to 11 years old, and we plan to submit them to the FDA and other regulators with urgency," said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.
Moderna also recently announced that Health Canada approved its vaccination, SPIKEVAXTM for individuals 12 and older.
"Health Canada's approval of our COVID-19 vaccine is an important milestone as it is our first full approval for Spikevax. I would like to thank Health Canada for their hard work throughout the process," said Stéphane Bancel, Chief Executive Officer of Moderna.
Beyond its vaccine offering, AstraZeneca PLC (NASDAQ:AZN) recently released promising results from its Phase III prophylaxis trial for its AZD7442 PROVENT—the first antibody combination (non-vaccine) modified to potentially provide long-lasting protection that has demonstrated prevention of COVID-19 in a clinical trial.
AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77% (95% confidence interval (CI): 46, 90), compared to placebo.
"The PROVENT data show that one dose of AZD7442, delivered in a convenient intramuscular form, can quickly and effectively prevent symptomatic COVID-19," said Myron J. Levin, MD, Professor of Pediatrics and Medicine, University of Colorado School of Medicine, US, and principal investigator on the trial. "With these exciting results, AZD7442 could be an important tool in our arsenal to help people who may need more than a vaccine to return to their normal lives."
For more information, please visit: https://biotech-today.com/heres-why-you-want-biotech-stocks-in-your-portfolio/
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for BioVaxys Technology Corp. advertising and digital media from the company directly. There may be 3rd parties who may have shares of BioVaxys Technology Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of BioVaxys Technology Corp. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of BioVaxys Technology Corp. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact Information:
FN Media Group, LLC
Media Contact e-mail:
U.S. Phone: +1(954)345-0611
SOURCE USA News Group